DiscoverBlood & CancerBlack patients with ES-SCLC get less chemo, CTCs may guide breast cancer treatment, and new FDA approvals for neuroblastoma and prostate cancer
Black patients with ES-SCLC get less chemo, CTCs may guide breast cancer treatment, and new FDA approvals for neuroblastoma and prostate cancer

Black patients with ES-SCLC get less chemo, CTCs may guide breast cancer treatment, and new FDA approvals for neuroblastoma and prostate cancer

Update: 2020-12-08
Share

Description

Blood & Cancer news stories:

  1. Black patients with ES-SCLC get less chemo but have better survival: https://bit.ly/33Rb5eB

  2. Should CTCs guide treatment choice in HR+, HER2– breast cancer?: https://bit.ly/3gn6shc

  3. New drug approved for relapsed/refractory neuroblastoma: https://bit.ly/2VMpvIy

  4. FDA approves first agent for PSMA-PET imaging in prostate cancer: https://bit.ly/36TAaY7


Contact Blood & Cancer at podcasts@mdedge.com.

Comments 
In Channel
loading
Download from Google Play
Download from App Store
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Black patients with ES-SCLC get less chemo, CTCs may guide breast cancer treatment, and new FDA approvals for neuroblastoma and prostate cancer

Black patients with ES-SCLC get less chemo, CTCs may guide breast cancer treatment, and new FDA approvals for neuroblastoma and prostate cancer

Medscape Professional Network